Category News

Merck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…

Read MoreMerck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

WuXi Biologics Introduces WuXia™ RidGS Platform for Antibiotic-Free Cell Line Development

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched WuXia™ RidGS, an advanced glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. Designed for antibiotic-free cell line development, this platform utilizes zinc finger…

Read MoreWuXi Biologics Introduces WuXia™ RidGS Platform for Antibiotic-Free Cell Line Development

Judo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney

Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA conjugates via megalin receptors. This mechanism enables targeted gene knockdown…

Read MoreJudo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney

Novartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial

Novartis presented promising 12-month results from its Phase III APPEAR-C3G study at the 2024 American Society of Nephrology (ASN) Kidney Week. These findings show that patients with C3 glomerulopathy (C3G) who received oral Fabhalta® (iptacopan) alongside supportive care maintained clinically…

Read MoreNovartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial

Lilly’s EBGLYSS™ Achieves Skin Clearance and Itch Relief in Atopic Dermatitis Patients

Eli Lilly and Company has reported encouraging findings regarding its treatment EBGLYSS, showing significant improvements in skin condition and itch relief for patients suffering from moderate-to-severe atopic dermatitis (eczema) who had previously been treated with dupilumab. These results, stemming from…

Read MoreLilly’s EBGLYSS™ Achieves Skin Clearance and Itch Relief in Atopic Dermatitis Patients

PharmaJet Study: Tropis® Needle-Free System Boosts Polio Immunization Coverage and Cuts Costs

PharmaJet has announced compelling results from a groundbreaking implementation study in Nigeria, showing that their Tropis® ID Needle-free System significantly enhances polio immunization coverage, reduces costs, and gains widespread support among healthcare workers. The study, conducted with partners including Nigeria’s…

Read MorePharmaJet Study: Tropis® Needle-Free System Boosts Polio Immunization Coverage and Cuts Costs